Overview
The main purpose of this study is to assess the efficacy of RO7268489 in adults with progressive multiple sclerosis (PMS) receiving ocrelizumab. After the end of the double-blind period, an open-label (OL) extension may allow eligible participants to receive open-label RO7268489.
Eligibility
Inclusion Criteria:
- PMS, in accordance with the revised 2017 McDonald criteria
- Expanded disability status scale (EDSS) at screening between 3.0 and 6.0 inclusive
Exclusion Criteria:
- MS relapse during the 6 months preceding the randomization date
- Lack of peripheral venous access
- History of alcohol or other drug abuse, in the opinion of the investigator, within 5 years prior to screening
- Inability to complete an magnetic resonance imaging (MRI)
- Contraindications to ocrelizumab mandatory pre-medications
- Treatment with intravenous immunoglobulin (IV Ig) or plasmapheresis within 12 weeks prior to screening


